Takeda Invests IDR 539 Billion to Build National Plasma Ecosystem
Global biopharmaceutical company Takeda is partnering with the Indonesian government to build a national plasma industry ecosystem to expand access to plasma-derived therapies (PDT), which are used to treat various serious and rare diseases. The strategic partnership involves the Ministry of Health, the Ministry of Investment and Downstreaming/Investment Coordinating Board (BKPM), and the Coordinating Ministry for Economic Affairs. As part of the cooperation, the Ministry of Health has designated Takeda as a pharmaceutical industry capable of conducting plasma fractionation to produce plasma-based therapies in Indonesia.
Health Minister Budi Gunadi Sadikin stated that this step marks an important milestone in strengthening national health resilience while supporting the development of the domestic biopharmaceutical industry. “This initiative reflects the Indonesian government’s commitment to building strategic industries in the health sector and ensuring the public has better access to essential and innovative treatments,” Budi said in a statement on Monday (13/7/2026).
Through this partnership, Takeda will carry out plasma collection and fractionation processes in stages as part of building the national plasma industry chain. The programme is also the first in Southeast Asia to focus on developing a sustainable, high-quality plasma collection system while supporting large-scale manufacturing of plasma-based therapies. As an initial phase, Takeda has prepared an investment of up to US$30 million, or approximately IDR 539 billion, over the next two years to establish several plasma banks in Indonesia. The results of this initial implementation will serve as a basis for evaluation by Takeda and the Ministry of Health before expanding into a national plasma bank network. The first plasma bank is targeted to begin operations in 2027 and will become part of Takeda’s BioLife plasma network, which already operates in various countries.
President of Plasma-Derived Therapies at Takeda, Ramy Riad, said the company is committed to supporting the development of a sustainable plasma ecosystem while expanding Indonesian patients’ access to plasma-based therapies. “This collaboration demonstrates Takeda’s commitment to expanding access to PDT while supporting the development of a sustainable plasma ecosystem in Indonesia,” Ramy said. He added that Takeda’s investment includes not only the construction of plasma collection infrastructure but also human resource development through healthcare worker training and knowledge transfer.
Beyond building plasma banks, Takeda will also explore the potential construction of a high-tech plasma-derived therapy manufacturing facility in Indonesia. The facility is expected to meet domestic market needs while opening export opportunities to international markets. Minister of Investment and Downstreaming/Head of BKPM Rosan P. Roeslani assessed that the cooperation holds strategic value as it not only brings new investment but also promotes technology transfer and enhances the capacity of the national workforce. “This is a strategic investment. In addition to bringing new investment, this partnership also opens opportunities for technology transfer, national human resource development, and job creation,” Rosan said. He added that the development of the plasma industry and therapy manufacturing has the potential to strengthen Indonesia’s position in the global health supply chain while supporting the country’s ambition to become a hub for health innovation and advanced pharmaceutical manufacturing in the region.
Global demand for plasma-derived therapies has been steadily increasing in recent years. However, countries in Southeast Asia, including Indonesia, still face challenges in ensuring the availability of these therapies due to limited plasma supply, low diagnosis rates, and a lack of awareness about diseases treatable with plasma-based therapies. Through this partnership, the government and Takeda hope to build a more sustainable plasma supply, enhance the capacity of the national health industry, and expand patient access to life-saving and life-sustaining therapies. While the plasma fractionation facility in Indonesia is still under study, collected plasma will be processed through Takeda’s global manufacturing network, prioritising the fulfilment of patient needs in Indonesia in accordance with applicable regulations.